News for Shilpa Medicare Limited (SHILPAMED.NS)

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NSHME.NS - Shilpa Medicare LtdQ4 2025 Shilpa Medicare Ltd Earnings CallMay 26, 2025 / 11:30AM G

"For traders, 24,870/81900 would act as a key support zone. Above this level, bullish sentiment is likely to continue. On the higher side, 25,150–25,250/82500-82800 would act as key resistance areas for traders," said Shrikant Chouhan, head, equity research, Kotak Securities.

In the Nifty 50 index, 38 stocks ended in the green, while 12 stocks closed in the red in today's trade.

Equity indices rise on positive developments, with Sensex up 0.56% and Nifty 50 up 0.6%, amid global cues.

**media[635122]**

Markets closed slightly higher after a narrow trading range, with several companies like JSW Energy and ITC Hotels set to announce Q4 results. Tata Power plans a significant capital expenditure, while Eicher Motors reported record quarterly sales. Balu Forge and Brigade Enterprises also saw substantial profit increases, and SBI is considering raising funds.

Key results: M&M, Indian Hotels, Coforge, CAMS, J&K Bank, Epigral, Ethos, Cigniti Technologies, Prataap Snacks, Bombay Dyeing, Unicommerce Solutions, Zee Media Corp, Stovec Inds, Vinyl Chemicals

PR NewswireRAICHUR, India, March 12, 2025 RAICHUR, India , March 12, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading

RAICHUR, India , March 12, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD).

Shilpa Medicare Limited's Telangana facilities receive EAEU GMP certification, boosting shares on NSE; expanding business in member countries.

Indian indices hit new record highs for the third straight session, boosted by the US Fed's rate cut. Analysts remain positive on the market's outlook, with Nifty expected to rise towards 26,200. Support is at 25,700.

Tech Mahindra, Wipro, Infosys, LTIMindtree and TCS were among the top losers on NSE.

Jul 08, 2024 / 05:30AM GMTOperator Ladies and gentlemen, good day, and welcome to Shilpa Medicare Limited business update call. (Operator Instructions) Please n

RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - recombinant human albumin® 20% (rHA), becoming the first Indian company to achieve this milestone. The positive results underscore rHA's potential as a viable alternative to plasma-derived human serum albumin, addressing a critical gap in global healthcare.

Shilpa Medicare Share Price: Northward surge in the stock price is attributed to the news that the company has received approval from the US Food and Drug Administration (USFDA) for its product, 'Bortezomib Injection NDA 212782

Shilpa Medicare, held by Madhusudhan Kela and Sunil Singhania, has returned 45% since its QIP allotment four months ago. Singhania's Abakkus Diversified Alpha Fund-2 received 6 lakh shares, while Kelas Cohesion MK Best Ideas Sub-Trust was allotted 8.79 lakh shares.

Aug 09, 2024 / 05:30AM GMTOperator Ladies and gentlemen, good day, and welcome to the Shilpa Medicare earnings call. (Operator Instructions) Please note that th

Landmark Prop, Rail Vikas Nigam, Shilpa Medicare, Marksans Pharma and Ahluwalia Contracts, hit their fresh 52-week highs during the day.

The Nifty Bank index closed 0.83 per cent down at 52660.35.